Citations

Showing 10 of 108104 citations.

The Intensivist's Perspective of Shock, Volume Management, and Hemodynamic Monitoring
Kashani, Kianoush , Omer, Tarig, Shaw, Andrew D., Kashani, Kianoush B , Omer, Tarig, Shaw, Andrew D.

Mayo Clinic

Clinical Journal of the American Society of Nephrology | April 4, 2022 | Volume: 17 | Issue: 5 | Pages: 706-716

10.2215/cjn.14191021 | PMID 35379765 Get It

One of the primary reasons for intensive care admission is shock. Identifying the underlying cause of shock (hypovolemic, distributive, cardiogenic, and obstructive) may lead to entirely different clinical pathways for management. Among patients with hypovolemic and distributive shock, fluid therapy is one of the leading management strategies. Although an appropriate amount of fluid administration might save a patient's life, inadequate (or excessive) fluid use could lead to more complications, including organ failure and mortality due to either hypovolemia or volume overload. Currently, intensivists have access to a wide variety of information sources and tools to monitor the underlying hemodynamic status, including medical history, physical examination, and specific hemodynamic monitoring devices. Although appropriate and timely assessment and interpretation of this information can promote adequate fluid resuscitation, misinterpretation of these data can also lead to additional mortality and morbidity. This article provides a narrative review of the most commonly used hemodynamic monitoring approaches to assessing fluid responsiveness and fluid tolerance. In addition, we describe the benefits and disadvantages of these tools.
Wernicke Encephalopathy
Fiester, Peter , Emerson, Blaze, Natter, Patrick , Rao, Dinesh , Sandhu, Sukhwinder J.S. , Soule, Erik

Mayo Clinic

Applied Radiology | April 4, 2022 | Volume: No volume available | Issue: No issue available | Pages: 48D-48G

10.37549/ar2656 Get It

Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have high‐risk cytogenetics: A meta‐analysis of randomized controlled trials
Chakraborty, Rajshekhar , Willson, Gloria , Gupta, Samiksha , Asghar, Noureen, Husnain, Muhammad , Aljama, Mohammed A. , Anwer, Faiz , Perrot, Aurore , Chakraborty, Rajshekhar , Perrot, Aurore , Anwer, Faiz , Siddiqi, Rabbia , Behera, Tapas Ranjan , Riaz, Irbaz Bin

Mayo Clinic

Cancer | April 4, 2022 | Volume: 128 | Issue: 12 | Pages: 2288-2297

10.1002/cncr.34211 | PMID 35377484 Get It

BackgroundDespite routine evaluation of cytogenetics in myeloma, little is known regarding the impact of high‐dose therapy (HDT) consolidation on overall survival (OS) or progression‐free survival (PFS) in patients who have high‐risk cytogenetics. The authors performed a meta‐analysis of randomized controlled trials (RCTs) to assess the heterogeneity of HDT efficacy according to cytogenetic risk.MethodsAll RCTs in patients who had newly diagnosed myeloma from 2000 to 2021 that compared upfront HDT versus standard‐dose therapy (SDT) consolidation were included. The primary objective was to assess the difference in HDT efficacy between standard‐risk and high‐risk cytogenetics in terms of the OS or PFS log(hazard ratio) (HR). The pooled OS and PFS HR was calculated according to cytogenetic‐risk subgroup using a random‐effects model, and heterogeneity (I2) (the percentage of total observed variability explained by between‐study differences) was assessed using an interaction test.ResultsAfter screening 3307 citations, 6 RCTs were included for PFS analysis, and 4 were included for OS analysis. The median follow‐up ranged from 3.1 to 7.8 years. The pooled OS HR for HDT versus SDT consolidation in patients with standard‐risk and high‐risk cytogenetics was 0.90 (95% confidence interval [CI], 0.70‐1.17; I2 = 0%) and 0.66 (95% CI, 0.45‐0.97; I2 = 0%), respectively. The difference in HDT efficacy in terms of OS between standard‐risk and high‐risk patients was statistically significant in favor of the high‐risk group (P for interaction = .03). The pooled PFS HR for HDT versus SDT was 0.65 (95% CI 0.56‐0.76; I2 = 0%) versus 0.52 (95% CI, 0.33‐0.83; I2 = 55%), respectively. The difference in HDT efficacy in terms of PFS between standard‐risk and high‐risk patients was not significant (P for interaction = .25).ConclusionsThe magnitude of OS benefit with upfront HDT is cytogenetics‐dependent. Patients with high‐risk cytogenetics should preferably receive upfront rather than delayed HDT consolidation.Lay Summary Upfront autologous stem cell transplantation improves overall survival in patients with newly diagnosed myeloma harboring high‐risk cytogenetics.
Imaging diffuse liver disease
Mathew, Rishi Philip , Venkatesh, Sudhakar K.

Mayo Clinic

Applied Radiology | April 4, 2022 | Volume: No volume available | Issue: No issue available | Pages: 13-20

10.37549/ar2604 Get It

MRI of endometriosis: A comprehensive review
Samreen, Jeton Naziya, Bookwalter, Candice A., Feldman, Myra , Sheedy, Shannon P. , Menias, Christine O. , VanBuren, Wendaline M. , Burnett, Tatnai L.

Mayo Clinic

Applied Radiology | April 4, 2022 | Volume: No volume available | Issue: No issue available | Pages: 6-12

10.37549/ar2603 Get It

Analysis of Preferred Music of Mechanically Ventilated Intensive Care Unit Patients Enrolled in a Randomized Controlled Trial
Heiderscheit, Annie , Johnson, Kaylie, Chlan, Linda L.

Mayo Clinic

Journal of Integrative and Complementary Medicine | April 4, 2022 | Volume: 28 | Issue: 6 | Pages: 517-529

10.1089/jicm.2021.0446 | PMID 35377238 Get It

Neuroimaging of pediatric abusive head trauma
Brucker, Justin, Kalina, Peter , Rolfes, Mary , Guérin, J.

Mayo Clinic

Applied Radiology | April 4, 2022 | Volume: No volume available | Issue: No issue available | Pages: 30-38

10.37549/ar2580 Get It

Radiofrequency ablation of an osteoid osteoma of the metacarpal
Bailey, Ryan , Siesener, Nathan J. , Davis, Ryan M. , Bailey, Ryan, Brogan, David M.

Mayo Clinic

Applied Radiology | April 4, 2022 | Volume: No volume available | Issue: No issue available | Pages: 45-47

10.37549/ar2556 Get It

Lost in translation—Challenges in drug development for inherited metabolic diseases
Sirrs, Sandra , Patterson, Marc C. , Lachmann, Robin

Mayo Clinic

Journal of Inherited Metabolic Disease | April 4, 2022 | Volume: 45 | Issue: 3 | Pages: 381-382

10.1002/jimd.12501 | PMID 35373847 Get It

Letter: Robotic-Assisted Neuroendovascular Intervention: Great Potential and Halted Expansion
Ghozy, Sherief , Ghozy, Sherief , Azzam, Ahmed Y , Dmytriw, Adam A.

Mayo Clinic

Neurosurgery | April 4, 2022 | Volume: 90 | Issue: 6 | Pages: e190-e191

10.1227/neu.0000000000001973 | PMID 35377347 Get It